Five things for pharma marketers to know: Thursday, July 12, 2018

Share this content:


Sen. Claire McCaskill's (D-MO) report on the opioid crisis found that three companies shipped 1.6 billion opioid doses to Missouri between 2012 and 2017. Lawsuits that could hold drug distributors responsible for hundreds of billions of dollars could be used for drug treatment and recovery in affected areas. (Axios)


Humana is partnering with Walgreens on retail-based primary care services. Two Walgreens locations in Kansas City, Missouri, will test the model. The partnership will help Walgreens compete with CVS-Aetna, according to an analyst from RBC Capital Markets. (AIS Health)


Sen. Ron Wyden (D-OR) is asking for information about President Donald Trump's conversation with Pfizer about drug prices. The senator wrote letters to both Pfizer and Health and Human Services Secretary Alex Azar requesting details on the agreement struck between Trump and Pfizer and the decision to hold off on price hikes. Wyden said the “agreement with Pfizer is long on theatrics and short on real and sustainable relief for patients.” (Endpoints)


Alphabet's Verily and ResMed are forming a startup focused on treating sleep apnea. About 80% of people with sleep apnea are undiagnosed and untreated, resulting in $150 billion in costs each year. The startup will focus on understanding the disease, raising awareness, and diagnosing people earlier. (CNBC)


Zogenix's experimental drug for severe epilepsy succeeded in its second late-stage study. GW Pharmaceuticals' drug derived from cannabis was the first approved to treat Dravet syndrome, a type of epilepsy. Zogenix plans to submit applications for approval before the end of 2018. (Reuters)

Share this content:
Scroll down to see the next article